Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial (Q102150511)
Jump to navigation
Jump to search
scientific article published on 16 November 2020
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial |
scientific article published on 16 November 2020 |
Statements
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial (English)
Joel S Perlmutter
Karen Marder
Richard M Dubinsky
Michael J Brownstein
Neal G Simon
Jeffrey D Long
Jon Yankey
Hilda T Maibach
Merit Cudkowicz
Christopher Coffey
Robin A Conwit
Codrin Lungu
Karen E Anderson
Steven M Hersch
Dixie J Ecklund
Eve M Damiano
Debra E Itzkowitz
Shifang Lu
Marianne K Chase
Jeremy M Shefner
Andrew McGarry
Brenda Thornell
Catherine Gladden
Michele Costigan
Padraig O'Suilleabhain
Frederick J Marshall
Amy M Chesire
Paul Deritis
Jamie L Adams
Peter Hedera
Kelly Lowen
H Diana Rosas
Amie L Hiller
Joseph Quinn
Kellie Keith
Andrew P Duker
Christina Gruenwald
Angela Molloy
Cara Jacob
Stewart Factor
Elaine Sperin
Danny Bega
Zsazsa R Brown
Lauren C Seeberger
Victor W Sung
Melanie Benge
Sandra K Kostyk
Allison M Daley
Susan Perlman
Valerie Suski
Patricia Conlon
Matthew J Barrett
Stephanie Lowenhaupt
Mark Quigg
Brenton A Wright
Elaine Most
Guy J Schwartz
Jessica Lamb
Rosalind S Chuang
Carlos Singer
Joyce A Moran
John R Singleton
Meghan Zorn
Paola V Wall
Carolyn Gray
Carolyn Drazinic
16 November 2020
16 November 2020
1 reference